Cargando…

Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant

PURPOSE: In the pre-clinical setting, hepatocellular bile salt accumulation impairs liver regeneration following partial hepatectomy. Here, we study the impact of cholestasis on portal vein embolization (PVE)-induced hypertrophy of the future liver remnant (FLR). METHODS: Patients were enrolled with...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Xinwei, Korenblik, Remon, Olij, Bram, Knapen, Robrecht R. M. M., van der Leij, Christiaan, Heise, Daniel, den Dulk, Marcel, Neumann, Ulf P., Schaap, Frank G., van Dam, Ronald M., Olde Damink, Steven W. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867667/
https://www.ncbi.nlm.nih.gov/pubmed/36680689
http://dx.doi.org/10.1007/s00423-023-02784-w
_version_ 1784876394677796864
author Chang, Xinwei
Korenblik, Remon
Olij, Bram
Knapen, Robrecht R. M. M.
van der Leij, Christiaan
Heise, Daniel
den Dulk, Marcel
Neumann, Ulf P.
Schaap, Frank G.
van Dam, Ronald M.
Olde Damink, Steven W. M.
author_facet Chang, Xinwei
Korenblik, Remon
Olij, Bram
Knapen, Robrecht R. M. M.
van der Leij, Christiaan
Heise, Daniel
den Dulk, Marcel
Neumann, Ulf P.
Schaap, Frank G.
van Dam, Ronald M.
Olde Damink, Steven W. M.
author_sort Chang, Xinwei
collection PubMed
description PURPOSE: In the pre-clinical setting, hepatocellular bile salt accumulation impairs liver regeneration following partial hepatectomy. Here, we study the impact of cholestasis on portal vein embolization (PVE)-induced hypertrophy of the future liver remnant (FLR). METHODS: Patients were enrolled with perihilar cholangiocarcinoma (pCCA) or colorectal liver metastases (CRLM) undergoing PVE before a (extended) right hemihepatectomy. Volume of segments II/III was considered FLR and assessed on pre-embolization and post-embolization CT scans. The degree of hypertrophy (DH, percentual increase) and kinetic growth rate (KGR, percentage/week) were used to assess PVE-induced hypertrophy. RESULTS: A total of 50 patients (31 CRLM, 19 pCCA) were included. After PVE, the DH and KGR were similar in patients with CRLM and pCCA (5.2 [3.3–6.9] versus 5.7 [3.2–7.4] %, respectively, p = 0.960 for DH; 1.4 [0.9–2.5] versus 1.9 [1.0–2.4] %/week, respectively, p = 0.742 for KGR). Moreover, pCCA patients with or without hyperbilirubinemia had comparable DH (5.6 [3.0–7.5] versus 5.7 [2.4–7.0] %, respectively, p = 0.806) and KGR (1.7 [1.0–2.4] versus 1.9 [0.8–2.4] %/week, respectively, p = 1.000). For patients with pCCA, unilateral drainage in FLR induced a higher DH than bilateral drainage (6.7 [4.9–7.9] versus 2.7 [1.5–4.2] %, p = 0.012). C-reactive protein before PVE was negatively correlated with DH (ρ = − 0.539, p = 0.038) and KGR (ρ = − 0.532, p = 0.041) in patients with pCCA. CONCLUSIONS: There was no influence of cholestasis on FLR hypertrophy in patients undergoing PVE. Bilateral drainage and inflammation appeared to be negatively associated with FLR hypertrophy. Further prospective studies with larger and more homogenous patient cohorts are desirable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-02784-w.
format Online
Article
Text
id pubmed-9867667
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-98676672023-01-23 Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant Chang, Xinwei Korenblik, Remon Olij, Bram Knapen, Robrecht R. M. M. van der Leij, Christiaan Heise, Daniel den Dulk, Marcel Neumann, Ulf P. Schaap, Frank G. van Dam, Ronald M. Olde Damink, Steven W. M. Langenbecks Arch Surg Research PURPOSE: In the pre-clinical setting, hepatocellular bile salt accumulation impairs liver regeneration following partial hepatectomy. Here, we study the impact of cholestasis on portal vein embolization (PVE)-induced hypertrophy of the future liver remnant (FLR). METHODS: Patients were enrolled with perihilar cholangiocarcinoma (pCCA) or colorectal liver metastases (CRLM) undergoing PVE before a (extended) right hemihepatectomy. Volume of segments II/III was considered FLR and assessed on pre-embolization and post-embolization CT scans. The degree of hypertrophy (DH, percentual increase) and kinetic growth rate (KGR, percentage/week) were used to assess PVE-induced hypertrophy. RESULTS: A total of 50 patients (31 CRLM, 19 pCCA) were included. After PVE, the DH and KGR were similar in patients with CRLM and pCCA (5.2 [3.3–6.9] versus 5.7 [3.2–7.4] %, respectively, p = 0.960 for DH; 1.4 [0.9–2.5] versus 1.9 [1.0–2.4] %/week, respectively, p = 0.742 for KGR). Moreover, pCCA patients with or without hyperbilirubinemia had comparable DH (5.6 [3.0–7.5] versus 5.7 [2.4–7.0] %, respectively, p = 0.806) and KGR (1.7 [1.0–2.4] versus 1.9 [0.8–2.4] %/week, respectively, p = 1.000). For patients with pCCA, unilateral drainage in FLR induced a higher DH than bilateral drainage (6.7 [4.9–7.9] versus 2.7 [1.5–4.2] %, p = 0.012). C-reactive protein before PVE was negatively correlated with DH (ρ = − 0.539, p = 0.038) and KGR (ρ = − 0.532, p = 0.041) in patients with pCCA. CONCLUSIONS: There was no influence of cholestasis on FLR hypertrophy in patients undergoing PVE. Bilateral drainage and inflammation appeared to be negatively associated with FLR hypertrophy. Further prospective studies with larger and more homogenous patient cohorts are desirable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-02784-w. Springer Berlin Heidelberg 2023-01-21 2023 /pmc/articles/PMC9867667/ /pubmed/36680689 http://dx.doi.org/10.1007/s00423-023-02784-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Chang, Xinwei
Korenblik, Remon
Olij, Bram
Knapen, Robrecht R. M. M.
van der Leij, Christiaan
Heise, Daniel
den Dulk, Marcel
Neumann, Ulf P.
Schaap, Frank G.
van Dam, Ronald M.
Olde Damink, Steven W. M.
Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
title Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
title_full Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
title_fullStr Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
title_full_unstemmed Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
title_short Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
title_sort influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867667/
https://www.ncbi.nlm.nih.gov/pubmed/36680689
http://dx.doi.org/10.1007/s00423-023-02784-w
work_keys_str_mv AT changxinwei influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT korenblikremon influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT olijbram influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT knapenrobrechtrmm influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT vanderleijchristiaan influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT heisedaniel influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT dendulkmarcel influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT neumannulfp influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT schaapfrankg influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT vandamronaldm influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant
AT oldedaminkstevenwm influenceofcholestasisonportalveinembolizationinducedhypertrophyofthefutureliverremnant